This is a preview of subscription content, access via your institution
Subscribe to Nature+
Get immediate online access to Nature and 55 other Nature journal
Subscribe to Journal
Get full journal access for 1 year
only $8.25 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
United States Congress. 21st Century Cures Act https://www.congress.gov/bill/114th-congress/house-bill/34/text.%20 (2016).
Centers for Medicare & Medicaid Services. FY 2020 IPPS/LTCH PPS final rule. https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/FY2020-IPPS-Final-Rule-Home-Page (2019).
Rising, J. P. & Moscovitch, B. PLoS One 10, e0117235 (2015).
Makower, J., Meer, A. & Denend, L. FDA impact on U.S. medical technology innovation: a survey of over 200 medical technology companies. https://www.advamed.org/sites/default/files/resource/30_10_11_10_2010_Study_CAgenda_makowerreportfinal.pdf (2010).
Holmes, D. R. Jr. et al. JACC Cardiovasc. Interv. 9, 626–628 (2016).
US Food and Drug Administration. Medical device innovation initiative white paper. https://www.fda.gov/about-fda/cdrh-innovation/medical-device-innovation-initiative-white-paper (2019).
Dhruva, S. S., Bero, L. A. & Redberg, R. F. J. Am. Med. Assoc. 302, 2679–2685 (2009).
US Food and Drug Administration. Report to Congress: Breakthrough Devices Program. https://www.fda.gov/media/124747/download (2019).
Hwang, T. J., Darrow, J. J. & Kesselheim, A. S. J. Am. Med. Assoc. 318, 2137–2138 (2017).
Kesselheim, A. S. et al. J. Am. Med. Assoc. 315, 1516–1518 (2016).
Krishnamurti, T., Woloshin, S., Schwartz, L. M. & Fischhoff, B. JAMA Intern. Med. 175, 1856–1858 (2015).
Rathi, V. K., Krumholz, H. M., Masoudi, F. A. & Ross, J. S. J. Am. Med. Assoc. 314, 604–612 (2015).
Agusti, A. & Sin, D. D. Clin. Chest Med. 35, 131–141 (2014).
Kramer, D. B., Xu, S. & Kesselheim, A. S. N. Engl. J. Med. 366, 848–855 (2012).
Martelli, N. et al. Cardiovasc. Interv. Radiol. 42, 1272–1278 (2019).
Zile, M. R. et al. Am. Heart J. 204, 139–150 (2018).
Shuren, J. & Califf, R. M. J. Am. Med. Assoc. 316, 1153–1154 (2016).
Judson, T. J., Dhruva, S. S. & Redberg, R. F. Br. Med. J. 365, l2190 (2019).
Centers for Medicare & Medicaid Services, US Food and Drug Administration. Program for parallel review of medical devices. Federal Register https://www.federalregister.gov/documents/2016/10/24/2016-25659/program-for-parallel-review-of-medical-devices (2016).
Centers for Medicare & Medicaid Services. Decision memo for next generation sequencing (NGS) for Medicare beneficiaries with advanced cancer (CAG-00450N). https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=290 (2018).
Foster, N. L., Mottola, K. & Hoffman, J. M. JAMA Neurol. 71, 399–400 (2014).
Reynolds, I. S., Rising, J. P., Coukell, A. J., Paulson, K. H. & Redberg, R. F. JAMA Intern. Med. 174, 1773–1779 (2014).
Roginiel, A. C., Dhruva, S. S. & Ross, J. S. Med. (Baltim.) 97, e12715 (2018).
US Food and Drug Administration. Breakthrough Devices Program: guidance for industry and Food and Drug Administration staff. https://www.fda.gov/media/108135/download (2018).
In the past 36 months, J.S.R. received research support through Yale University from Medtronic, Inc. and the FDA to develop methods for postmarket surveillance of medical devices (U01FD004585), from the CMS to develop and maintain performance measures that are used for public reporting (HHSM-500-2013-13018I), and from the Blue Cross Blue Shield Association to better understand medical technology evaluation. J.S.R. currently receives research support through Yale University from Johnson & Johnson to develop methods of clinical trial data sharing, from the FDA to establish the Yale-Mayo Clinic Center for Excellence in Regulatory Science and Innovation (CERSI) program (U01FD005938), from the Medical Device Innovation Consortium as part of the National Evaluation System for Health Technology (NESTcc), from the Agency for Healthcare Research and Quality (R01HS022882), from the National Heart, Lung and Blood Institute of the National Institutes of Health (NIH) (R01HS025164, R01HL144644), and from the Laura and John Arnold Foundation to establish the Good Pharma Scorecard at Bioethics International and to establish the Collaboration for Research Integrity and Transparency (CRIT) at Yale. S.S.D. reports receiving travel support from the FDA and the National Evaluation System for Health Technology (NESTcc). J.L.J. has received support from the FDA through the CERSI program. Research reported in this publication was supported by National Heart, Lung and Blood Institute of the National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung, and Blood Institute or the National Institutes of Health under Award Number T35HL007649.
About this article
Cite this article
Johnston, J.L., Dhruva, S.S., Ross, J.S. et al. Early experience with the FDA’s Breakthrough Devices program. Nat Biotechnol 38, 933–938 (2020). https://doi.org/10.1038/s41587-020-0636-7